Attovia Therapeutics, Inc. 8K

Attovia Therapeutics reported Q2 2026 results, early clinical validation of ATTO-1310, a robust development pipeline, and an upsized IPO that extends its cash runway into 2030 despite ongoing losses.

Attovia Therapeutics, Inc. filed a current report to furnish its second quarter 2026 financial results and corporate update, highlighting preliminary clinical proof of concept for its lead candidate ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, outlining plans to initiate multiple Phase 2 trials for ATTO-1310 and first-in-human Phase 1 trials for ATTO-2306 and ATTO-1091 in the first half of 2027, and reporting that an upsized initial public offering generated approximately $332.4 million in gross proceeds (about $305.4 million net), extending the company’s projected cash runway into 2030 despite a net loss of $20.7 million for the quarter ended June 30, 2026.

Filing Facts

CIK

2058707

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-380215

Alert Tier

7